A Phase 3 interventional study of VLA15 and Placebo in Lyme Disease, sponsored by Pfizer. Recruiting at 22 sites in 2 countries. Open to participants aged 7 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.
Among the 54 studies in Lyme Disease with a site in United States, this one is the 4th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 52nd registered.
98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.
Browse Lyme Disease studies →15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–70
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 18+ · Women only
Children's National Research Institute · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 7 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 10
First in 1996; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,712 is above the median of 120 across 52 interventional studies indexed under Lyme Disease.
Median enrollment 72 across the 33 interventional studies, 410 across the 21 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 54 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Lyme Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Lyme Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500506Phase 3PfizerA Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | 2026-12-04 |
| NCT05776251Columbia UniversitytaVNS for Persistent Symptoms From Lyme Disease | 2026-11 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06397794Children's National Research InstituteNavigating Pregnancy and Parenthood With Lyme Disease | 2026-12-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 54 studies in Lyme Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine.
This study is seeking participants who:
All participants in this study will receive a total of 1 dose through a shot in the upper arm, either VLA15 or saline shot (saltwater).
The study will compare the experiences of people receiving the study vaccine or saltwater shot.
Participants will take part in this study for about 12 months. During this time, they will have 4 planned clinic visits. The clinic visits may include having a health check, giving a small amount of blood and getting the study vaccine or saltwater as a shot at the first visit.
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine, VLA15, in Healthy Participants ≥7 Years of Age
Participants will be randomized in a 5:1 ratio to receive either one dose of VLA15 or placebo (saline) at the first visit. This study will use an external data monitoring committee (EDMC). The EDMC is independent of the Pfizer study team and includes only external members. The EDMC charter describes the role of the EDMC in more detail.
Approximately 1712 participants will be enrolled in the study.
Healthy individuals 7 years of age and older who have received 4 prior doses of active VLA15 from the C4601003 study, have a blood sample taken post dose 4, are willing to comply with all study procedures, and provide signed informed consent will be enrolled. Pregnant or breastfeeding individuals and fertile individuals who are unwilling or unable to use effective contraceptive methods as outlined in this protocol will not be enrolled. Individuals who have contraindication to vaccination, conditions or treatments that can inhibit the ability to mount an immune response to a vaccine, or other conditions that may increase the risk of study participation will be excluded from this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single injection in the muscle (IM) of VLA15 at Visits 1, two years after their 4th dose of VLA15
Biological: VLA15
Participants will receive a single injection in the muscle (IM) of Saline at Visits 1, two years after their 4th dose of VLA15
Biological: Placebo
Participants will receive a single injection in the muscle (IM) of VLA15 at Visits 1, one year after their 4th dose of VLA15
Biological: VLA15
Participants will receive a single injection in the muscle (IM) of saline at Visits 1, one year after their 4th dose of VLA15
Biological: Placebo
VLA15 injection IM
Saline Injection
Percentage of participants reporting prespecified local reactions
Time frame: Within 7 days following each study intervention administration
Percentage of participants reporting prespecified systemic events
Time frame: Within 7 days following each study intervention administration
Percentage of participants reporting adverse events (AEs)
Time frame: Through 1 month following study intervention administration
Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)
Time frame: Through study completion, up to approximately 12 months.
Percentage of participants reporting serious adverse events (SAEs)
Time frame: Through study completion, up to approximately 12 months.
Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)
Objective to determine non-inferiority of Dose 5 compared to Dose 4 in all participants when there is a 1 year gap between Dose 4 and Dose 5.
Time frame: At 1 month after completion of Dose 5
Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).
Difference in seroresponse rate between 1 month after Dose 5 and 1 month after Dose 4 for each serotype in all participants ≥7 years of age who received a fifth dose of VLA15 1 year after their fourth dose of VLA15.
Time frame: At 1 month after completion of Dose 5
Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)
Objective to determine non-inferiority of Dose 5 compared to Dose 4 in adult participants when there is a 1 year gap between Dose 4 and Dose 5.
Time frame: At 1 month after completion of Dose 5
Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)
Objective to determine non-inferiority of Dose 5 compared to Dose 4 in all participants when there is a 2 year gap between Dose 4 and Dose 5.
Time frame: At 1 month after completion of Dose 5
Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)
Objective to describe the immune response following Dose 5 compared to Dose 4 in pediatric participants when there is a 1 year gap between Dose 4 and Dose 5.
Time frame: At 1 month after completion of Dose 5
Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)
Objective to describe the immune response following Dose 5 compared to Dose 4 in all participants (by age group) when there is a 2 year gap between Dose 4 and Dose 5.
Time frame: At 1 month after completion of Dose 5
Geometric mean fold rise (GMFR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)
Objective to describe the immune response following Dose 5 compared to Dose 4 in all participants when there is a 1 or 2 year gap between Dose 4 and Dose 5.
Time frame: At just prior to Dose 5 and 1 month after completion of Dose 5
Geometric mean concentration (GMC) of anti-OspA IgG concentrations for each serotype (ST1-ST6)
Objective to describe the immune response following Dose 5 compared to Dose 4 in all participants when there is a 1 or 2 year gap between Dose 4 and Dose 5.
Time frame: At 1 month after completion of Dose 5
Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).
Difference in seroresponse rate between 1 month after Dose 5 and 1 month after Dose 4 for each serotype in adult participants ≥18 years of age who received a fifth dose of VLA15 1 year after their fourth dose of VLA15.
Time frame: At 1 month after completion of Dose 5
Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).
Difference in seroresponse rate between 1 month after Dose 5 and 1 month after Dose 4 for each serotype in all participants ≥7 years of age who received a fifth dose of VLA15 2 years after their fourth dose of VLA15.
Time frame: At 1 month after completion of Dose 5
Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).
Seroresponse rate at 1 month after Dose 5 using pre-Dose 1 and pre-Dose 5 seroresponse rates as baseline in all participants who received a fifth dose of VLA15 1 year and 2 years after their fourth dose of VLA15.
Time frame: At 1 month after completion of Dose 5
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VLA15